<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04438213</url>
  </required_header>
  <id_info>
    <org_study_id>2000027951</org_study_id>
    <secondary_id>MISP59625</secondary_id>
    <nct_id>NCT04438213</nct_id>
  </id_info>
  <brief_title>Ertugliflozin in Acute Heart Failure</brief_title>
  <official_title>Ertugliflozin in Acute Heart Failure: Cardio-renal and Diuretic Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects on heart failure signs and symptoms of
      the use of either ertugliflozin, metolazone or placebo, in conjunction with intravenous loop
      diuretic use in acute settings and chronic oral loop diuretic therapy.

      There are two general purposes for this study. The proposed study is both larger and more
      rigorous than essentially all PK/PD studies that form the basis of current practice with loop
      diuretics as well as all studies looking at add-on thiazide therapy (current
      guideline-recommended adjuvant). The second is to generate a mechanistic understanding of the
      pleotropic cardio-renal factors with chronic therapy that differentiate ertugliflozin from
      traditional diuretics particularly in how they maintain reduced blood volume without the
      complication of over-diuresis and volume depletion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized placebo controlled mechanistic study to understand the utility of
      ertugliflozin in acute and post-acute hospitalized heart failure patients with or without
      diabetes, compared to both placebo and the active control metolazone. The broad study design
      will be designed around evaluation of change in gold standard determined body fluid spaces
      (blood volume, extracellular fluid, total body water), administering a sodium chloride
      challenge, and collecting the necessary biospecimens to test our hypotheses. The general
      study design will randomize to ertugliflozin vs. placebo early during IV diuretic therapy
      with continuation post discharge for a total therapy of 6 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Natriuretic effect of adjuvant to loop diuretic therapy</measure>
    <time_frame>1 day</time_frame>
    <description>The natriuretic effect (urine sodium concentration) of each arm with loop diuretic therapy will be measured by the urine sodium output.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline to day 7 of total body water by add-on to loop diuretic therapy (Chronic)</measure>
    <time_frame>7 days</time_frame>
    <description>The primary outcome of the chronic effects of add-on placebo, thiazide-like diuretic, or SGLT2 inhibitor is to determine the change in total body water from baseline to day 7</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline to 6 weeks total body water by add-on to loop diuretic therapy (Chronic)</measure>
    <time_frame>6 weeks</time_frame>
    <description>The primary outcome of the chronic effects of add-on placebo, thiazide-like diuretic, or SGLT2 inhibitor is to determine the change in total body water from baseline to 6 weeks.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Acute Heart Failure</condition>
  <arm_group>
    <arm_group_label>Ertugliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metolazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin</intervention_name>
    <description>Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo</description>
    <arm_group_label>Ertugliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metolazone</intervention_name>
    <description>Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo</description>
    <arm_group_label>Metolazone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will be randomized to six weeks of treatment with either ertugliflozin, metolazone, or a placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A clinical diagnosis of ADHF with at least one objective sign of volume overload
             (rales, edema, elevated JVP, or preadmission weight gain)

          2. As judged by the treating physician, a projected need and ability to tolerate
             treatment with an extended need for IV diuretics with the goal of significant fluid
             removal (i.e., goal &gt;1L/day net fluid loss)

          3. Chronic daily oral loop diuretic dose &gt; or equal to 20mg furosemide equivalents for at
             least one month prior to admission

          4. eGFR 30 mL/min/1.73 m2

          5. Signed informed consent

        Exclusion Criteria:

          1. Current use or plan to initiate renal replacement therapy or ultrafiltration this
             hospital admission

          2. Significant bladder dysfunction or urinary incontinence

          3. Inability to comply with the serial urine collection procedures

          4. Current use of a thiazide or thiazide like diuretics or use within 5 half-lives of the
             drug, including metolazone

          5. Prior heart transplant, critical stenotic valvular disease or complex congenital heart

          6. History of type 1 diabetes, diabetic ketoacidosis, &quot;brittle&quot; diabetes or frequent
             hypoglycemia or severe hypoglycemic episodes requiring emergent intervention (ER visit
             or EMS response, glucagon administration or forced oral carbs) in the last 3 months

          7. History of or current urosepsis or frequent urinary tract infections

          8. Anemia with hemoglobin &lt;8g/dL (due to required phlebotomy for the study)

          9. Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jennifer Tainsh, RN</last_name>
    <phone>203-737-3571</phone>
    <email>jennifer.tainsh@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Jeffrey Testani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 3, 2020</study_first_submitted>
  <study_first_submitted_qc>June 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2020</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ertugliflozin</keyword>
  <keyword>Metolazone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol</mesh_term>
    <mesh_term>Metolazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

